The identification of auto-antibodies in pancreatic cancer patient sera using a naturally fractionated Panc-1 cell line

Cancer Biomarkers

Volumn 7, Issue 1, 2010, Pages 25-37

  Li, Chen ^a   Kim, Hye Yeung ^b   Vuong, Huy ^a   Patwa, Tasneem ^c   Pal, Manoj ^d   Brand, Randall E ^e   Simeone, Diane M ^b   Lubman, David M ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c PFIZER INC   (United States)

^d Genomics Institute   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

humoral response; microarray; Outlier sum; Panc 1; Pancreatic cancer; PGK

Indexed keywords

AUTOANTIBODY; PHOSPHOGLYCERATE KINASE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CELL FRACTIONATION; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MALE; MASS FRAGMENTOGRAPHY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MICROARRAY; RANK SUM TEST; SERUM;

AGED; ANTIBODIES, NEOPLASM; AUTOANTIBODIES; CELL LINE, TUMOR; HUMANS; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS; PHOSPHOGLYCERATE KINASE; PROTEIN ARRAY ANALYSIS; ROC CURVE;

EID: 78149238298     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2010-0145     Document Type: Article

References (33)

1. A. Jemal, R. Siegel, E. Ward, T. Murray, J.Q. Xu, C. Smigal and M.J. Thun, Cancer Statistics, 2006, CA Cancer J Clin 56 (2006), 106-130.
2. C. Rosty and M. Goggins, Early detection of pancreatic carcinoma, Hematol Oncol Clin North Am 16 (2002), 37-52.
3. G. Garcea, C.P. Neal, C.J. Pattenden, W.P. Steward and D.P. Berry, Molecular prognostic markers in pancreatic cancer: A systematic review, Eur J Cancer 41 (2005), 2213-2236.
4. E.M. Tan, Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis, J Clin Investig 108 (2001), 1411-1415.
5. C.A. Casiano, M. Mediavilla-Varela and E.M. Tan, Tumor-associated arrays for the serological diagnosis of cancer, Mol & Cel, Proteomics 5 (2006), 1745-1759.
6. C. Desmetz, T. Maudelonde, A. Mange and J. Solassol, Identifying autoantibody signatures in cancer: a promising challenge, Expert Rev Proteomics 6 (2009), 377-386.
7. J.C. Hall, L. Casciola-Rosen and A. Rosen, Altered structure of autoantigens during apoptosis, Rheum Dis Clin North Am 30 (2004), 455-471.
8. K.M. Pollard, D.K. Lee, C.A. Casiano, M. Bluthner, M.M. Johnston and E.M. Tan, The autoimmunity-inducing xeno-biotic mercury interacts with the autoantigen fibrillarin and modifies its molecular and antigenic properties, J Immunol 158 (1997), 3521-3528.
9. P.J. Utz and P. Anderson, Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens, Arthritis Rheum 41 (1998), 1152-1160.
10. A. Rosen, C. Casciola-Rosen and F. Wigley, Role of metal-catalyzed oxidation reactions in the early pathogenesis of scle-roderma, Curr Opin Rheumatol 9 (1997), 538-543.
11. K. Ben-Mahrez, D. Thierry, I. Sorokine, A. Danna-Muller and M. Kohiyama, Detection of circulating antibodies against c-myc protein in cancer patient sera, Br J Cancer 57 (1998), 529-534.
12. M.L. Disis, E. Calenoff, G. McLaughlin, A.E. Murphy, W. Chen, B. Groner, M.L. Jeschke, N. Lydon, E. McGlynn, R.B. Livingston, R. Moe and M.A. Cheever, Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer, Cancer Res 54 (1994), 16-20.
13. M.L. Disis and M.A. Cheever, Oncogenic proteins as tumor antigens, Curr Opin Immunol 8 (1996), 637-642.
14. T. Soussi, p53 Antibodies in the sera of patients with various types of cancer: a review, Cancer Res 60 (2000), 1777-1788.
15. F.M. Brichory, D.E. Misek, A.M. Yim, M.C. Krause, T.J. Giordano, D.G. Beer and S.M. Hanash, An immune response manifested by the common occurrence of annexins I and II au-toantibodies and high circulating levels of IL-6 in lung cancer, Proc Natl Acad Sci USA 98 (2001), 9834-9829.
16. S. Gnjatic, C. Wheeler, M. Ebner, E. Ritter, A. Murray, N.K. Altorki, C.A. Ferrara, H. Hepburne-Scott, S. Joyce, J. Koop-man, M.B. McAndrew, N. Workman, G. Ritter, R. Fallon and L.J. Old, Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conforma-tional protein arrays, Clin Canc Res 15 (2009), 4733-4741.
17. C. Desmetz, C. Bascoul-Mollevi, P. Rochaix, P.J. Lamy, A. Kramar, P. Rouanet, T. Maudelonde, A. Mange and J. So-lassol, Identification of a New Panel of Serum Autoantibod-ies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women, J Immunol Methods 341 (2009), 50-58.
18. K.S. Looi, E.S. Nakayasu, R. de Diaz, E.M. Tan, I.C. Almeida and J.Y. Zhang, Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma, J Proteome Res 7 (2008), 4004-4012.
19. Q. Xia, X.T. Kong, G.A. Zhang, X.J. Hou, H. Qiang and R.Q. Zhong, Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer, Biochem Biophys Res Commun 330 (2005), 526-532.
20. Y. Hamanaka, Y. Suehiro, M. Fukui, K. Shikichi, K. Imai and Y. Hinoda, Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer, Int J Cancer 103 (2003), 97-100.
21. Y. Kotera, J.D. Fontenot, G. Pecher, R.S. Metzgar and O.J. Finn, Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon-cancer patients, Cancer Res 54 (1994), 2856-2860.
22. J. Raedle, G. Oremek, M. Welker, W.K. Roth, W.F. Caspary and S. ZeuzeFm, p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma, Pancreas 13 (1996), 241-246.
23. F. Yan, A. Sreekumar, B. Laxman, A.M. Chinnaiyan, D.M. Lubman and T.J. Barder, Protein microarrays using liquid phase fractionation of cell lysates, Proteomics 3 (2003), 1228-1235.
24. T.H. Patwa, C. Li, L.M. Poisson, H.Y. Kim, M. Pal, D. Ghosh, D.M. Simeone and D.M. Lubman, The identification of phos-phoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a naturalprotein microarray, Eletrophoresis 12 (2009), 2215-2226.
25. L. Canelle, J. Bousquet, C. Pionneau, L. Deneux, N. Imam-Sghiouar, M. Caron and R. Joubert-Caron, An efficient proteomics-based approach for the screening of autoantibod-ies, J Immunol Methods 229 (2005), 77-89.
26. R. Tibshirani and T. Hastie, Outlier sums for differential gene expression analysis, Biostatistics 8 (2007), 2-8.
27. M. Lieber, J. Mazzetta, W. Nelson-Rees, M. Kaplan and G. Todaro, Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas, Int J Cancer 15 (1975), 741-747.
28. S.A. Tomlins, D.R. Rhodes, S. Perner, S.M. Dhanasekaran, R. Mehra, X.W. Sun, S. Varambally, C.H. Cao, J. Tchinda, R. Kuefer, C. Lee, J.E. Montie, R.B. Shah, K.J. Pienta, M.A. Rubin and A.M. Chinnaiyan, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, Science 310 (2005), 644-648.
29. F. Dayan, D. Roux, M.C. Brahimi-Horn, J. Pouyssegur and N.M. Mazure, The oxygensensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha, Cancer Res 66 (2006), 3688-3698.
30. J. Wang, J. Dai, Y. Jung, C.L. Wei, Y. Wang, A.M. Havens, P.J. Hogg, E.T. Keller, K.J. Pienta, J.E. Nor, C.Y. Wang and R.S Taichman, A glycolytic mechanism regulating an angiogenic switch in prostate cancer, Cancer Res 67 (2007), 149-159.
31. M. Kurayoshi, N. Oue, H. Yamamoto, M. Kishida, A. Inoue, T. Asahara, W. Yasui and A. Kikuchi, Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion, Cancer Res 66 (2006), 10439-10448.
32. D. Zieker, I. Konigsrainer, F. Traub, K. Nieselt, B. Knapp, C. Schillinger, C. Stirnkorb, F. Fend, H. Northoff, S. Kupka, B.L. Brucher and A. Konigsrainer, PGK1 a potential marker for peritoneal dissemination in gastric cancer, Cell Physiol, Biochem 21 (2008), 429-436.
33. S. Shichijo, K. Azuma, N. Komatsu, M. Ito, Y. Maeda, Y. Ishi-hara and K. Itoh, Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2 (+) colon cancer, Clin Cancer Res 10 (2004), 5828-5836.